SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Escalating geopolitical tensions in the Middle East are driving significant community discussion around SPY, with market participants sharply divided on whether concerns over oil supply and broader stability will lead to a major downturn or present a "buy the dip" opportunity.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd ($INDO) is trending amidst escalating geopolitical tensions in the Middle East, with reports of attacks on Saudi oil facilities and disruptions in the Strait of Hormuz sparking expectations of surging oil prices. The community is actively discussing a potential massive short squeeze, comparing its low-float dynamics to previous parabolic runs during global conflicts and anticipating significant gains.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Surging as escalating Middle East tensions, including threats to oil supply routes and facilities, propel the energy sector, Battalion Oil (BATL) is captivating traders who are noting its explosive momentum and discussing potential for a short squeeze due to its low float.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the community debates the market's reaction to the escalating US-Iran conflict, with many anticipating a significant downturn due to surging oil prices and inflation concerns, while others expect a 'V-recovery' based on historical resilience and the belief that the geopolitical event is already priced in.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Heightened geopolitical tensions impacting global LNG supply routes, coupled with strong anticipation for its upcoming earnings, are driving significant conversation around Venture Global. The community is actively discussing the company's rapid production expansion, perceived undervaluation relative to peers, and the potential for a substantial short squeeze.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending due to escalating geopolitical tensions in the Middle East following reported US-Israeli strikes on Iran and subsequent regional retaliation, raising significant concerns about global oil supply disruptions, particularly within the critical Strait of Hormuz. The community is actively discussing a potential surge in crude prices, with many anticipating oil could reach $100 or higher amid fears of a prolonged conflict and a short squeeze in the energy sector.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending amid community anticipation of surging crude oil prices due to heightened Middle East geopolitical tensions, complemented by its strategic positioning for expanded Venezuela production and negotiations for a major Iraq oilfield.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending amid escalating geopolitical tensions in the Middle East, with reports of attacks on oil facilities and threats to critical shipping routes like the Strait of Hormuz driving intense community discussion about a potential surge in crude oil prices and significant upside for integrated energy majors.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing a massive rally following an earnings beat and aggressive revenue projections for its next-generation 800G and 1.6T optical transceivers, driven by the AI data center buildout. While bulls are celebrating potential revaluation and short squeeze, skeptics question management's ability to execute on these ambitious targets and highlight recent share dilution.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as investors brace for potential market volatility, driven by escalating geopolitical tensions and widespread concerns over an overvalued tech sector, leading the community to actively discuss accumulating bearish positions and hedging against a Nasdaq downturn.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Recommendation of "Hold" by Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six research firms that are presently covering the firm, Marketbeat Ratings...

BTIG Research Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

BTIG Research reaffirmed a "buy" rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Wednesday...

NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Decrease in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) was the recipient of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Increase in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 3,527,843 shares, an...

New Strong Sell Stocks for January 27th

DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of "Moderate Buy" by Brokerages

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the company...

NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at BTIG Research

BTIG Research reaffirmed a "buy" rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday...

<ul class="summary-bullets"><li>The move is a major step toward FDA approval of NRX-100, its investigational drug.</li><li>Currently, no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.</li><li>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting.</li></ul>NRx Pharmaceuticals, Inc. (NRXP) on Wednesday announced that it has licensed Real World Evidence (RWE) from more than 70,000 U.S. patients who received either intravenous ketamine or nasal S-ketamine as part of their treatment.The move is a major step toward FDA approval of its investigational drug, NRX-100 (preservative-free ketamine), aimed at treating suicidal ideation in patients with depression and suicidal tendencies.&nbsp;<h2 class="st-heading-2">Collaboration With Osmind</h2>The RWE data comes from Osmind, a neuropsychiatry technology platform used across U.S. clinics, providing detailed, regulatory-grade patient records. This joint effort allows NRx to submit a comprehensive dataset to the FDA in support of Accelerated Approval for NRX-100 under its Fast Track Designation.&nbsp;The approach could mark a breakthrough, as currently no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals' stock&nbsp;</a>traded over 21% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ territory from ‘bearish’ the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Preliminary Findings And Expectations</h2>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting. Results suggested rapid improvement in depression and suicidal ideation with intravenous ketamine.&nbsp;NRx anticipates that analysis of the full 70,000-patient dataset will provide even stronger evidence to support the FDA submission.<blockquote>“An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials.”-Jonathan Javitt, Chairman and CEO, NRx Pharmaceuticals</blockquote>NRXP stock has declined by over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a hand holding a medical syringe seen displayed in front of the NRx Pharmaceuticals logo.

Why Did NRXP Stock Surge 21% Pre-Market Today?

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.

Equity

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.


D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital restated a "buy" rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Monday...

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

NRX Pharmaceuticals Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$1.86
Prev Close	$1.93
Open	$1.90
Dividend Yield	0.00%
50-Day Moving Average	$2.14
Beta	1.10
Avg. Volume	1.8M
PE Ratio	-0.79

52-Week High	$3.84
52-Week Low	$1.58
Market Capitalization	$59.28M
EPS (Annual)	-$2.36
Price to Book	-2.00
Revenue Per Employee	N/A

NRXP
NRX Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NRXP News

NRXPNRX Pharmaceuticals Inc